Rani Therapeutics Holdings, Inc. (NASDAQ:RANI – Get Rating) major shareholder South Cone Investments Limited acquired 3,200 shares of the business’s stock in a transaction dated Monday, November 21st. The stock was purchased at an average cost of $7.87 per share, for a total transaction of $25,184.00. Following the completion of the acquisition, the insider now directly owns 6,545,856 shares of the company’s stock, valued at approximately $51,515,886.72. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
South Cone Investments Limited also recently made the following trade(s):
- On Friday, November 18th, South Cone Investments Limited bought 13,300 shares of Rani Therapeutics stock. The stock was purchased at an average price of $7.49 per share, for a total transaction of $99,617.00.
Rani Therapeutics Stock Performance
Shares of RANI traded up $0.52 during mid-day trading on Thursday, reaching $7.89. The company had a trading volume of 51,226 shares, compared to its average volume of 48,497. The stock has a 50 day moving average of $7.74 and a two-hundred day moving average of $9.71. The company has a quick ratio of 14.02, a current ratio of 14.02 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $389.45 million, a P/E ratio of -6.58 and a beta of 0.03. Rani Therapeutics Holdings, Inc. has a 52-week low of $5.62 and a 52-week high of $32.50.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several analysts have commented on RANI shares. UBS Group started coverage on shares of Rani Therapeutics in a research note on Tuesday, October 11th. They set a “buy” rating for the company. HC Wainwright assumed coverage on shares of Rani Therapeutics in a research report on Wednesday, July 27th. They set a “buy” rating and a $22.00 target price for the company.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes.
- Get a free copy of the StockNews.com research report on Rani Therapeutics (RANI)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.